Loading
PBP1510 is a monoclonal antibody from Prestige Biopharma Limited, in registered phase 2 trials for pancreatic ductal adenocarcinoma.
PBP1510 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Prestige Biopharma Limited, in pancreatic ductal adenocarcinoma. A monoclonal antibody, as described in the registry record. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
A monoclonal antibody, as described in the registry record.
1.PBP1510 binds its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"PBP1510" OR ABSTRACT:"PBP1510") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PBP1510, not a curated reading list.
Shares Pancreatic ductal adenocarcinoma and the tags pipeline, registry-only.
Shares Pancreatic ductal adenocarcinoma and the tags pipeline, registry-only.
Shares Pancreatic ductal adenocarcinoma and the tags pipeline, registry-only.
Shares Pancreatic ductal adenocarcinoma and the tags pipeline, registry-only.
Shares Pancreatic ductal adenocarcinoma and the tags pipeline, registry-only.
Shares Pancreatic ductal adenocarcinoma and the tags pipeline, registry-only.
Shares Pancreatic ductal adenocarcinoma and the tags pipeline, registry-only.
Shares Pancreatic ductal adenocarcinoma and the tags pipeline, registry-only.